论文部分内容阅读
目的探讨雄激素受体(AR)在前列腺癌细胞系LNCaP中分选出的干/祖(S/P)细胞和非干/祖(non S/P)细胞的不同作用。方法采用流式细胞术从LNCaP中分选出S/P细胞和Non S/P细胞,使用慢病毒载体携带AR转入两种细胞,在不同的雄激素浓度(1 nmol/L和10 nmol/L)培养条件下,应用四甲基偶氮唑盐(MTT)实验,前列腺细胞球体形成实验,琼脂糖凝胶克隆形成实验,细胞迁移实验来比较AR在两种细胞中的不同作用。结果 AR转入S/P细胞,细胞生长受到抑制(P<0.05),形成前列腺球的能力下降(P<0.05),成瘤能力减弱(P<0.05),细胞迁移能力下降(P<0.05);反之,AR转入non S/P细胞,细胞生长能力增强(P<0.05),成瘤能力加强(P<0.05),细胞迁移能力增强(P<0.05)。结论 AR在前列腺癌细胞系LNCaP中分选出的S/P和non S/P细胞表达不同,发挥相反作用,这可能是现有前列腺癌内分泌治疗失败的原因之一。
Objective To investigate the different roles of androgen receptor (AR) in stem / progenitor (S / P) cells and non S / P cells in prostate cancer cell line LNCaP. Methods S / P cells and Non S / P cells were sorted out from LNCaP by flow cytometry and transfected into both cells with lentiviral vector at different concentrations of androgen (1 nmol / L and 10 nmol / L), MTT test, prothrombocytopenia, agarose colony formation assay and cell migration assay were used to compare the different roles of AR in the two cell lines. Results The proliferation of S / P cells was inhibited by AR (P <0.05), the ability of forming prostate sphere was decreased (P <0.05), the ability of tumorigenesis was decreased (P <0.05) (P <0.05). On the other hand, AR transfected into non-S / P cells enhanced the cell growth ability (P <0.05), enhanced tumorigenicity (P <0.05) and enhanced cell migration ability (P <0.05). CONCLUSIONS: The expression of AR in non-S / P and S / P cells differentiated from prostate cancer cell line LNCaP may play an opposite role. This may be one of the reasons for the failure of endocrine therapy in prostate cancer.